Method of evaluating myelosuppressive state
Patent Number: 6649352
Date of First Priority Issue: Friday January 29th, 1999
Date Issued: Tuesday November 18th, 2003
Assignee: Center for Molecular Medicine and Immunology (Belleville, NJ)
Inventors: Blumenthal, Rosalyn D. (Belleville, NJ); Lew, Walter (Caldwell, NJ); Juweid, Malik (Bloomfield, NJ); Alisauskas, Rita (Hopatcong, NJ); Ying, Zhiliang (East Brunswick, NJ); Goldenberg, David M. (Mendham, NJ)
From Class: Use
Comments: No comments
After chemotherapy or radiation therapy, the myeloid compartment of the immune response is suppressed, due to destruction of the myeloid stem cell compartment. This patent provides a kit that allows the determination of myelosuppression, and therefore can be used to guide the amount of myelo-stimulatory therapy (ie G-CSF) that should be administered. The kit measures alone or in combination the levels of Flt3 ligand, TGF, and TNF from a "sample" taken from a patient.
View this patent on the USPTO website.
Added to StemCellPatents.com on Monday October 16th, 2006
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.